Table 1 Main characteristics of included studies

Ando

et al [23]

(1999)

Japan

HD ^a

38

1800

1638

–

–

12

33/5

51 ± 13

54 ± 11

↓TC ^c, ↓TG ^d,

↔HDL ^e

Ateya

et al [24]

(2017)

Egypt

HD

49

1000

500

250

–

16

27/22

14.6 ± 2.7

14.7 ± 2.7

↔TC, ↓TG,

↔HDL,

↔LDL ^f,

↔MDA ^g

,↑GPx ^h,↑SOD ⁱ

Bouzidi

et al [25]

(2010)

Algeria

CRF ^b

40

2100

693

252

–

12

22/18

61 ± 14

61 ± 14

↓TG,

↑GPx,

↑SOD,

↔HDL, ↔LDL,

↔TC

Alexopoulos

et al [26]

(2004)

Greece

IgA Nephropathy

28

3000

850

580

192

22/6

39 ± 10

41 ± 12

↔TG

Gharekhani

et al [27]

(2016)

Iran

HD

45

1800

1080

720

–

16

25/20

57.2 ± 15.19

56.8 ± 13.09

↔LDL,↓TG,↓TC,↓HDL

Jabbari

et al [28]

(2016)

Iran

HD

117

3000

–

12

75/25

61.05 ± 17.42

64.58 ± 12.61

↔TC, ↔TG, ↔LDL

, ↑HDL

Khajehdehi [29]

(2000)

Iran

HD

30

1500

–

8

15/15

32.4 ± 9.2

32.7 ± 10.7

↔TC,

↓ TG, ↓LDL, ↑HDL

Moeinzadeh [30]

et al (2011)

Iran

HD

52

3000

540

360

–

24

36/16

58.34 ± 14.36

57.76 ± 15.56

↑HDL, ↔LDL, ↔TC,

↔TG

Naini et al [31]

(2015)

Iran

PD^l

90

3000

540

360

–

8

51/39

59.36 ± 13.4

57.7 ± 16.3

↓DBP ^j, ↓SBP ^k,

↔HDL

,↔LDL,

↔TC,

↔TG

Pettersson [32]

et al

(1994)

Sweden

IgA Nephropathy

32

6000

2800

1530

–

24

25/7

42

39

↔HDL,

↔TC

,↓TG,

↔LDL,

↔SBP,

↔DBP

Schmitz [33]

et al

(2002)

USA

HD

24

4000

1760

960

–

48

11/13

54 ± 3

52 ± 6

↓TG

Tayyebi-Khosroshahi et al [34]

(2013)

Iran

HD

88

3000

540

360

–

8

63/25

48.60

51.50

↔HDL, ↔LDL, ↔TC, ↔TG

Tayyebi-Khosroshahi et al [35]

(2010)

Iran

HD

75

3000

540

360

–

8

49/26

49.3 ± 1.8

48.8 ± 2.7

↑GPX, ↓MDA, ↑SOD,